TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35566530

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) group, n = 18, 10 weeks of lower limb resistance training with a concentric phase at maximum velocity
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group, n = 12
Number of subjects: 30
Study: 33356004

Group type: EXPERIMENTAL
Intervention: 40 mg furosemide
Number of subjects: 0
Study: 34418858

Group type: EXPERIMENTAL
Intervention: Triceps surae stretching (4 × 60 seconds)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham group (forearm stretching)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (age-matched healthy elderly, no stretching treatment)
Number of subjects: 19
Study: 32444619

Group type: EXPERIMENTAL
Intervention: Compassionate coach (CC) image
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Loving kindness meditation (LKM)
Number of subjects: 200
Study: 34423693

Group type: EXPERIMENTAL
Intervention: Client-Centered (CC) intervention with telerehabilitation (TR) method
Number of subjects: 38
Study: 32087340

Group type: EXPERIMENTAL
Intervention: Compendium of implementation strategies to add or enhance smoking cessation services during lung screening
Number of subjects: 26

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 26
Study: 34813467

Group type: EXPERIMENTAL
Intervention: eM-KOFL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: pM-KOFL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: vM-KOFL
Number of subjects: 0

Group type: COMPARATOR
Intervention: S-KOFL
Number of subjects: 0
Study: 32977254

Group type: EXPERIMENTAL
Intervention: 200 mL low‐dose anthocyanin (5 mg/100 g) QGP nectar
Number of subjects: 28

Group type: COMPARATOR
Intervention: Raspberry cordial (control)
Number of subjects: 28
Study: 34331348

Group type: EXPERIMENTAL
Intervention: Fedratinib 400 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32365355

Group type: EXPERIMENTAL
Intervention: L-thyroxine
Number of subjects: 638

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 638
Study: 34044816

Group type: EXPERIMENTAL
Intervention: Breastfeeding Heritage and Pride program (BHP)
Number of subjects: 0
Study: 32011655

Group type: EXPERIMENTAL
Intervention: Lacosamide at a concentration of 30 μM
Number of subjects: 0
Study: 35199262

Group type: EXPERIMENTAL
Intervention: HIE plus CTI
Number of subjects: 347

Group type: COMPARATOR
Intervention: HIE alone
Number of subjects: 347
Study: 36056636

Group type: EXPERIMENTAL
Intervention: Intensive lipid lowering therapy (rosuvastatin 40 mg + ezetimibe 10 mg daily)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard lipid lowering therapy (atorvastatin 40 mg daily)
Number of subjects: 104
Study: 33832531

Group type: EXPERIMENTAL
Intervention: Gap Balancing (GB) technique
Number of subjects: 96

Group type: COMPARATOR
Intervention: Measured Resection (MR) technique
Number of subjects: 96
Study: 36198032

Group type: EXPERIMENTAL
Intervention: In-person visits
Number of subjects: 1769

Group type: COMPARATOR
Intervention: Telemedicine visits
Number of subjects: 1769
Study: 33617333

Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate using MOSES technology
Number of subjects: 60

Group type: COMPARATOR
Intervention: Holmium laser enucleation of the prostate
Number of subjects: 60
Study: 32819429

Group type: EXPERIMENTAL
Intervention: CCTA/CT-FFR strategy (group A)
Number of subjects: 1216

Group type: COMPARATOR
Intervention: Usual care (group B)
Number of subjects: 1216
Study: 33740564

Group type: EXPERIMENTAL
Intervention: Brainstem auditory evoked responses (BAER)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bone conduction (BC)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Brainstem auditory evoked responses (BAER) and Bone conduction (BC)
Number of subjects: 24
Study: 33196464

Group type: EXPERIMENTAL
Intervention: MVT‐602 (0.01 and 0.03 nmol/kg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: MVT‐602
Number of subjects: 21

Group type: COMPARATOR
Intervention: KP54 (9.6 nmol/kg)
Number of subjects: 21
Study: 33403688

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact with father
Number of subjects: 95

Group type: COMPARATOR
Intervention: Cot
Number of subjects: 95

Group type: COMPARATOR
Intervention: Fathers' arms
Number of subjects: 95
Study: 36335639

Group type: EXPERIMENTAL
Intervention: High-dose trivalent influenza vaccine
Number of subjects: 5210
Study: 32914237

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: R0 resected tumors
Number of subjects: 180
Study: 32916855

Group type: EXPERIMENTAL
Intervention: Blues Program indicated prevention intervention
Number of subjects: 220

Group type: COMPARATOR
Intervention: Group membership
Number of subjects: 220
Study: 35331539

Group type: EXPERIMENTAL
Intervention: Paleolithic‐based low‐carbohydrate diet with calorie‐counting method (PLCD‐CC)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Paleolithic‐based low‐carbohydrate diet with portion‐control method (PLCD‐PC)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Moderate‐carbohydrate diet with calorie‐counting method (MCD‐CC)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Moderate‐carbohydrate diet with portion‐control method (MCD‐PC)
Number of subjects: 80
Study: 33293185

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 10 µg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 100
Study: 34101892

Group type: EXPERIMENTAL
Intervention: Rivoceranib 201 mg with food
Number of subjects: 44

Group type: COMPARATOR
Intervention: Rivoceranib 201 mg without food
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Rivoceranib 81 mg with food
Number of subjects: 44

Group type: COMPARATOR
Intervention: Rivoceranib 81 mg without food
Number of subjects: 44
Study: 33146345

Group type: EXPERIMENTAL
Intervention: CBD 300 mg/day
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 36229671

Group type: EXPERIMENTAL
Intervention: ePRO web-app (ABATON RA)
Number of subjects: 10
Study: 33402102

Group type: EXPERIMENTAL
Intervention: SOX regimen (oxaliplatin combined with S-1) for six cycles (three cycles followed by another three cycles for group A)
Number of subjects: 524

Group type: COMPARATOR
Intervention: SOX regimen (oxaliplatin combined with S-1) for three cycles (group B)
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: SOX regimen (oxaliplatin combined with S-1) for six cycles (group A)
Number of subjects: 524
Study: 32510130

Group type: EXPERIMENTAL
Intervention: NK3Ra (MLE4901) 40 mg orally twice a day for 7 days
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Kisspeptin-10 (4 µg/kg/h i.v.) after NK3Ra treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Kisspeptin-10 (4 µg/kg/h i.v.) without NK3Ra treatment
Number of subjects: 15
Study: 34591356

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan 97/103 mg bid (n=103)
Number of subjects: 201

Group type: COMPARATOR
Intervention: enalapril 10 mg bid (n=98)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan 97/103 mg bid
Number of subjects: 201

Group type: COMPARATOR
Intervention: enalapril 10 mg bid
Number of subjects: 201
Study: 33033091

Group type: EXPERIMENTAL
Intervention: Patient-controlled regional analgesia (PCRA) - ultrasound-guided subgluteal sciatic catheterisation, continuous infusion of 0.2% ropivacaine (15 mL loading dose, 8 mL/hour background, 6 mL patient-controlled bolus)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PCIA) - morphine in boluses of 1 mg as needed, background infusion at 1 mg/hour
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: PCRA
Number of subjects: 52

Group type: COMPARATOR
Intervention: PCIA
Number of subjects: 52
Study: 36364907

Group type: EXPERIMENTAL
Intervention: 300 mg Irvingia gabonensis (IG) extract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 0
Study: 32565344

Group type: EXPERIMENTAL
Intervention: MenACYW-TT
Number of subjects: 3344

Group type: COMPARATOR
Intervention: MCV4-DT
Number of subjects: 3344

Group type: EXPERIMENTAL
Intervention: MenACYW-TT and MCV4-DT
Number of subjects: 3344
Study: 35581610

Group type: EXPERIMENTAL
Intervention: Lateral Thinking Method (LTM)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Traditional Didactic Method
Number of subjects: 272
Study: 33693481

Group type: EXPERIMENTAL
Intervention: Moderate dose alcohol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32179922

Group type: EXPERIMENTAL
Intervention: Inhalational methoxyflurane (Penthrox®)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Intramuscular tramadol
Number of subjects: 343
Study: 36409480

Group type: COMPARATOR
Intervention: Irrigation fluid at room temperature (RT group)
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Irrigation fluid at body temperature (BT group)
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Mortality, health-related quality of life, and complication frequency
Number of subjects: 541
Study: 33462622

Group type: EXPERIMENTAL
Intervention: Bloodletting (3 scheduled bloodlettings after a 3-month run-in period with 35 μg ethinylestradiol plus 2 mg cyproterone acetate)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Observation (after a 3-month run-in period with 35 μg ethinylestradiol plus 2 mg cyproterone acetate)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Bloodletting
Number of subjects: 33
Study: 33990812

Group type: EXPERIMENTAL
Intervention: Vitrification solutions with sucrose (VS1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitrification solutions without sucrose (VS2 and VS4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Warming solution containing trehalose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Warming solution containing sucrose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (directly subjected to IVM)
Number of subjects: 0
Study: 33438761

Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 33798525

Group type: EXPERIMENTAL
Intervention: Thermal ablation of the defect margin after endoscopic mucosal resection (EMR‐T)
Number of subjects: 1049
Study: 32787783

Group type: EXPERIMENTAL
Intervention: Prophylactic methoxamine infusion at 1 μg/kg/min (Group M1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Prophylactic methoxamine infusion at 2 μg/kg/min (Group M2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Prophylactic methoxamine infusion at 3 μg/kg/min (Group M3)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Prophylactic methoxamine infusion at 4 μg/kg/min (Group M4)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Prophylactic methoxamine infusion (all groups)
Number of subjects: 80
Study: 33894009

Group type: EXPERIMENTAL
Intervention: Acupuncture in addition to usual care for three days (acupuncture points: Pericardium‐6, Stomach‐36, Liver‐3, Yin Tang)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Usual care only (control group)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Acupuncture in addition to usual care
Number of subjects: 112
Study: 33605586

Group type: EXPERIMENTAL
Intervention: nCRT followed by surgery
Number of subjects: 0
Study: 33538444

Group type: EXPERIMENTAL
Intervention: Computer-aided intraoperative navigation (Ci-Navi)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional intraoperative navigation methods
Number of subjects: 52
Study: 32664033

Group type: COMPARATOR
Intervention: Placebo expectation group (expectation to receive a placebo)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Drug expectation group (expectation to receive a fast-operating antidepressant)
Number of subjects: 94

Group type: COMPARATOR
Intervention: No treatment group (no expectation, no placebo)
Number of subjects: 94
Study: 35157756

Group type: EXPERIMENTAL
Intervention: Dural puncture epidural
Number of subjects: 141

Group type: COMPARATOR
Intervention: Standard epidural
Number of subjects: 141
Study: 32331038

Group type: EXPERIMENTAL
Intervention: Guided-care (combinatorial pharmacogenomic testing)
Number of subjects: 1298

Group type: EXPERIMENTAL
Intervention: Guided-care (combinatorial pharmacogenomic testing) with gene-drug interactions
Number of subjects: 1298

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 1298
Study: 35114727

Group type: EXPERIMENTAL
Intervention: Psychoeducational family intervention (PFI)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 137
Study: 32918892

Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI 100/62.5/25 μg
Number of subjects: 2439

Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI 200/62.5/25 μg
Number of subjects: 2439

Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI 100/31.25/25 μg
Number of subjects: 2439

Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI 200/31.25/25 μg
Number of subjects: 2439

Group type: COMPARATOR
Intervention: FF/VI 100/25 μg
Number of subjects: 2439

Group type: COMPARATOR
Intervention: FF/VI 200/25 μg
Number of subjects: 2439

Group type: EXPERIMENTAL
Intervention: All pooled treatment groups
Number of subjects: 2439

Group type: EXPERIMENTAL
Intervention: FF/UMEC 62.5 μg/VI
Number of subjects: 2439

Group type: EXPERIMENTAL
Intervention: FF/UMEC 31.25 μg/VI
Number of subjects: 2439

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 2439
Study: 35914695

Group type: EXPERIMENTAL
Intervention: Ozonated Water (OW)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: KTP Laser
Number of subjects: 50

Group type: COMPARATOR
Intervention: Chlorhexidine (CHX)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Rose Bengal Photosensitizer (RBP)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Er, YAG Laser
Number of subjects: 50
Study: 32867803

Group type: EXPERIMENTAL
Intervention: Late parenteral nutrition (late-PN)
Number of subjects: 96
Study: 35305317

Group type: EXPERIMENTAL
Intervention: MVA-NP+M1 (1·5 × 10^8 plaque-forming units)
Number of subjects: 2152

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 2152

Group type: EXPERIMENTAL
Intervention: MVA-NP+M1
Number of subjects: 2152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2152
Study: 35051685

Group type: EXPERIMENTAL
Intervention: Placebo presented as propranolol
Number of subjects: 60

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (generic)
Number of subjects: 60
Study: 35657468

Group type: EXPERIMENTAL
Intervention: Telemedicine visits for contraception (phone or video)
Number of subjects: 1414

Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 1414

Group type: EXPERIMENTAL
Intervention: Housing insecurity
Number of subjects: 1414
Study: 33924871

Group type: EXPERIMENTAL
Intervention: Genetically predicted arachidonic acid (% of total fatty acids increase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetically predicted arachidonic acid
Number of subjects: 0
Study: 32877910

Group type: EXPERIMENTAL
Intervention: Imaginal retraining (self-help manual)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Control group (active or wait-list)
Number of subjects: 345
Study: 616063481

Group type: EXPERIMENTAL
Intervention: T+CEF (3 cycles of docetaxel followed by 3 cycles of CEF)
Number of subjects: 1014

Group type: EXPERIMENTAL
Intervention: TX+CEX (docetaxel plus capecitabine followed by 3 cycles of cyclophosphamide, epirubicin and capecitabine)
Number of subjects: 1014

Group type: COMPARATOR
Intervention: V+CEF (3 cycles of weekly vinorelbine followed by 3 cycles of CEF)
Number of subjects: 1014

Group type: EXPERIMENTAL
Intervention: Adjuvant trastuzumab (for HER2+ BC)
Number of subjects: 1014
Study: 35581629

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/day for 6 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 55
Study: 33522512

Group type: EXPERIMENTAL
Intervention: 2 mA tDCS during virtual reality exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation during virtual reality exposure
Number of subjects: 0
Study: 35557256

Group type: EXPERIMENTAL
Intervention: tVNSab (pulse width = 200 ms; pulse frequency = 30 Hz)
Number of subjects: 7

Group type: COMPARATOR
Intervention: SHAM (time-control visit with no current applied)
Number of subjects: 7
Study: 33847156

Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN) for kidney and tumor segmentation on single-phase CT scans
Number of subjects: 319
Study: 33571743

Group type: EXPERIMENTAL
Intervention: Access control measures on workstations
Number of subjects: 773

Group type: COMPARATOR
Intervention: Regional and organizational level privacy regulations
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Single hospital-wide EMR
Number of subjects: 773
Study: 32562395

Group type: EXPERIMENTAL
Intervention: Ringer Lactate (RL)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Normal Saline (NS)
Number of subjects: 72
Study: 35237953

Group type: EXPERIMENTAL
Intervention: HT‐ESPB catheter
Number of subjects: 30

Group type: COMPARATOR
Intervention: Interscalene catheter
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HT‐ESPB
Number of subjects: 30

Group type: COMPARATOR
Intervention: Interscalene
Number of subjects: 30
Study: 32081517

Group type: EXPERIMENTAL
Intervention: NefroPortatil mobile application
Number of subjects: 52
Study: 33210997

Group type: EXPERIMENTAL
Intervention: Trial preparation (sildenafil tablet 20 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference preparation (sildenafil tablet 20 mg)
Number of subjects: 20
Study: 36086930

Group type: EXPERIMENTAL
Intervention: Dexamethasone OMP (5 mg/week)
Number of subjects: 30

Group type: COMPARATOR
Intervention: DPCP contact sensitization
Number of subjects: 30
Study: 34085830

Group type: EXPERIMENTAL
Intervention: Particle Swarm Optimization (PSO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Genetic Algorithm (GA)
Number of subjects: 0
Study: 32185595

Group type: EXPERIMENTAL
Intervention: CFα late‐start: CFα on day 4 + GnRH antagonist from day 8 + recFSH from day 11 (when needed)
Number of subjects: 113

Group type: COMPARATOR
Intervention: CFα standard start: CFα on day 2 + GnRH antagonist from day 6 + recFSH from day 9 (when needed)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: CFα late‐start
Number of subjects: 113

Group type: COMPARATOR
Intervention: CFα standard regimen
Number of subjects: 113
Study: 34725792

Group type: EXPERIMENTAL
Intervention: PIEB delivered at 125 mL·hr-1 (G125)
Number of subjects: 90

Group type: COMPARATOR
Intervention: PIEB delivered at 250 mL·hr-1 (G250)
Number of subjects: 90
Study: 34414606

Group type: EXPERIMENTAL
Intervention: RenalGuard® system (RG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current practice (control group)
Number of subjects: 0
Study: 32232743

Group type: EXPERIMENTAL
Intervention: 3D-TLRC
Number of subjects: 106

Group type: COMPARATOR
Intervention: 2D-TLRC
Number of subjects: 106
Study: 34471952

Group type: EXPERIMENTAL
Intervention: Robotic pancreaticoduodenectomy (RPD)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Open pancreaticoduodenectomy (OPD)
Number of subjects: 92
Study: 33525526

Group type: COMPARATOR
Intervention: DHA supplementation
Number of subjects: 10320
Study: 36296919

Group type: EXPERIMENTAL
Intervention: Standardized Red Orange Extract
Number of subjects: 60
Study: 34147125

Group type: EXPERIMENTAL
Intervention: ACD, BBC, and ABR grafting
Number of subjects: 40

Group type: COMPARATOR
Intervention: ACD with β‐tricalcium phosphate (β‐TCP) granules and ABR grafting
Number of subjects: 40
Study: 32865096

Group type: EXPERIMENTAL
Intervention: Cranial electrotherapy stimulation (CES) pretreatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: No pretreatment (control group)
Number of subjects: 80
Study: 35279929

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM)
Number of subjects: 760

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 760
Study: 34461224

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 0
Study: 32601120

Group type: EXPERIMENTAL
Intervention: Bilateral STN deep brain stimulation (DBS) plus optimal drug therapy (ODT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Optimal drug therapy (ODT) alone
Number of subjects: 28
Study: 35569129

Group type: EXPERIMENTAL
Intervention: Dupilumab (600 mg induction dose, followed by 300 mg every 2 weeks for patients ≥60 kg; 400 mg loading dose followed by 200 mg every 2 weeks for patients <60 kg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 27
Study: 33549820

Group type: EXPERIMENTAL
Intervention: Progressive elastic band resistance exercise training (peRET) for 12 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 27
Study: 34709130

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (sitting position, no exercise)
Number of subjects: 16
Study: 33175585

Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg daily)
Number of subjects: 3730

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3730
Study: 35325767

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 40
Study: 35372879

Group type: EXPERIMENTAL
Intervention: Oxalate decarboxylase (OxDC)
Number of subjects: 33
Study: 33273258

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (28 sessions over 8 weeks)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Prucalopride (2 mg/d before breakfast over 32 weeks)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 560

Group type: COMPARATOR
Intervention: Prucalopride
Number of subjects: 560
Study: 34876848

Group type: EXPERIMENTAL
Intervention: Acupuncture at Sanyinjiao (SP6) and Yinlingquan (SP9)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Lornoxicam
Number of subjects: 84
Study: 33716173

Group type: EXPERIMENTAL
Intervention: Supervised exercise (EX) plus 1% testosterone topical gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supervised exercise (EX) plus placebo gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 0
Study: 32063519

Group type: EXPERIMENTAL
Intervention: Work-related rhinitis (WRR)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Non-work-related rhinitis (non-WRR)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group (no nasal symptoms)
Number of subjects: 161
Study: 35761271

Group type: EXPERIMENTAL
Intervention: Once-weekly exenatide (EQW)
Number of subjects: 14665